Organism | Homo sapiens, human |
---|---|
Tissue | bladder |
Cell Type | smooth muscle cells |
Morphology | spindle-shaped; elongated (non-differentiated) |
Growth Properties | Adherent |
Biosafety Level |
1 [These primary cells are not known to harbor an agent recognized to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. Cells derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens.
ATCC recommends that appropriate safety procedures be used when handling all primary cells and cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures are provided in Laboratory Safety: Principles and Practice, 2nd ed. (ASM Press, Washington, DC) (Fleming et al., 1995) and Caputo, J.L. Biosafety procedures in cell culture. (1988) J. Tissue Culture Methods 11:223. Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online at http://www.cdc.gov/biosafety/publications/bmbl5/index.htm.] Human Material Precaution All tissues used for isolation are obtained under informed consent and conform to HIPAA standards to protect the privacy of the donor’s personal health information. It is best to use caution when handling any human cells. We recommend that all human cells be accorded the same level of biosafety consideration as cells known to carry HIV. With infectious virus assays or viral antigen assays, even a negative test result may leave open the possible existence of a latent viral genome. Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease | normal |
Age | Lot-specific |
Gender | Lot-specific |
Ethnicity | Lot-specific |
Applications | An ideal culture model for the study or development of a potential diagnostic method for the early detection of bladder cancer cells, reconstruction studies, and advancement of cancer research. |
Product Format | frozen 1.0 mL |
Storage Conditions | -130ºC or below |
Comments | hBSMC are cryopreserved at P2 and marketed as secondary cells (cells have been isolated, plated, and expanded in culture vessels twice prior to cryopreservation) to ensure the highest viability and proliferation efficiency. These cells, when transiently transfected using TransfeX Transfection Reagent (ATCC®ACS-4005™), express high levels of GFP. |
---|
Complete Growth Medium |
Table 1. If using the Vascular Smooth Muscle Cell Growth Kit, add the indicated volume for each of the following components
Antimicrobials and phenol red are not required for proliferation but may be added if desired. The recommended volume of either of the optional components (GA solution or PSA solution) to be added to the complete growth media is summarized in Table 2. Table 2. Addition of Antimicrobials/Antimycotics and Phenol Red (Optional)
|
|||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subculturing |
1. Passage normal bladder fibroblast cells when culture has reached approximately 80% confluence. 2. Warm both the Trypsin-EDTA for Primary Cells (ATCC® PCS-999-003) and the Trypsin Neutralizing Solution (ATCC® PCS-999-004) to room temperature prior to dissociation. Warm complete growth medium to 37°C prior to use with the cells. 3. For each flask, carefully aspirate the spent media without disturbing the monolayer. 4. Rinse the cell layer two times with 3 to 5 mL DPBS (ATCC® 30-2200) to remove residual traces of serum. 5. Add pre-warmed trypsin-EDTA solution (1 to 2 mL for every 25 cm2) to each flask. 6. Gently rock each flask to ensure complete coverage of the trypsin-EDTA solution over the cells, and then aspirate the excess fluid off of the monolayer. 7. Observe the cells under the microscope. When the cells pull away from each other and round up (typically within 3 to 5 minutes), remove the flask from the microscope and gently tap it from several sides to promote detachment of the cells from the flask surface. 8. When the majority of cells are detached, quickly add an equal volume of Trypsin Neutralizing Solution to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized. 9. Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the flask.10. Add 3 to 5 mL DPBS to the flask to collect any additional cells that might have been left behind. 11. Transfer the cell/DPBS suspension to the centrifuge tube containing the trypsin-EDTA dissociated cells. 12. Repeat steps 10 and 11 as needed until all cells have been collected from the flask. 13. Centrifuge the cells at 150 x g for 3 to 5 minutes. 14. Aspirate the neutralized dissociation solution from the cell pellet and re-suspend the cells in 2 to 8 mL fresh, pre-warmed, complete growth medium. 15. Count the cells and seed new flasks at a density of 2,500 to 5,000 cells per cm2. 16. Place newly seeded flasks in a 37°C, 5% CO2, incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding. |
Volume | 1.0 mL |
---|---|
Sterility Tests | Bacteria and Yeast: Negative Mycoplasma: Negative |
Viral Testing | Hepatitis B: Negative |
C of A | Certificate of Analysis |
Basic Documentation | Product Sheet Certificate of Analysis SDS |
---|